Bavarian Noridc gains 3.5% amid WHO mpox strategy announcment 📈

19:03 27 āļŠāļīāļ‡āļŦāļēāļ„āļĄ 2024

Danish pharmaceutical company, Bavarian Nordic (BAVA.DK) is trading up more than 3% today and climbing near the highs of early August. It's hard to find justification for this other than yesterday's announcement by the World Health Organization (WHO), which approved an initial $135 million package to accelerate and coordinate the fight against a potential increase in global monkeypox (mpox) virus infections. The WHO program aims to prevent and fund prevention, both on the part of scientists and collaborating institutions. 

  • News of the virus is creating elevated, speculative volatility in the stocks of companies that stand to profit from the sale of vaccines such as Bavarian, Emergent BioSolutions (EBS.US) and Moderna (MRNA.US) and Biontech (BNTX.US), which are only in the approval stage for their mRNA products. 
  • African regulators and health ministry officials estimate that about 200,000 doses are currently available, of the vaccine against the 10 million needed. So far, Bavarian has donated about 15,000 doses to Africa, while Emergent has donated 50000. 
  • The most difficult situation is in Africa, in the Congo region, although in relation to the population the number of cases is still relatively small. So far, the virus has also been detected in Sweden and the Philippines.

Bavarian has told the African Center for Disease Control and Prevention (CDC) that it is capable of delivering 10 million doses of the vaccine by the end of 2025 and about 2 million doses, later this year. By some experts, the Bavarian vaccine is touted as safer, against Emergent. The National Institute of Allergy and Infectious Diseases, will hold a conference on August 29-30 on mpox research and control of virus expansion. 

āđ€āļĢāļīāđˆāļĄāđ€āļ—āļĢāļ”āļ—āļąāļ™āļ—āļĩāļ§āļąāļ™āļ™āļĩāđ‰ āļŦāļĢāļ·āļ­ āļĨāļ­āļ‡āđƒāļŠāđ‰āļšāļąāļāļŠāļĩāļ—āļ”āļĨāļ­āļ‡āđāļšāļšāđ„āļĢāđ‰āļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡

āđ€āļ›āļīāļ”āļšāļąāļāļŠāļĩ āļĨāļ­āļ‡āļšāļąāļāļŠāļĩāđ€āļ”āđ‚āļĄāđˆ āļ”āļēāļ§āļ™āđŒāđ‚āļŦāļĨāļ”āđāļ­āļ›āļĄāļ·āļ­āļ–āļ·āļ­ āļ”āļēāļ§āļ™āđŒāđ‚āļŦāļĨāļ”āđāļ­āļ›āļĄāļ·āļ­āļ–āļ·āļ­

Bavarian Nordic (D1 interval)

The stock has traded almost twice as high since the 2023 minima. Driving valuations are, among other things, expectations for increased demand and production of mpox vaccines.

Source: xStation5

Historically, Bavarian Nordic's shares have been characterized by high volatility, and the last five years can hardly be described as exceptionally successful for the company. However, there have been isolated price spikes in which Bavarian's shares have gained 2 and more than 3 times. 

Source: xStation5

Revenues, earnings and financial multiples dashboards of Bavarian Nordic

Source: XTB Research, Bloomberg Finance L.P.

Source: XTB Research, Bloomberg Finance L.P.

āļŦāļļāđ‰āļ™:
āļāļĨāļąāļšāđ„āļ›

āļ‚āđˆāļēāļ§āđƒāļ™āļ•āļĨāļēāļ”āļāļēāļĢāđ€āļ‡āļīāļ™

25.07.2025
18:23

DE40: āļ™āļąāļāļĨāļ‡āļ—āļļāļ™āļĒāļļāđ‚āļĢāļ›āđ€āļĢāļīāđˆāļĄāļĢāļ°āļĄāļąāļ”āļĢāļ°āļ§āļąāļ‡ āļŦāļĨāļąāļ‡āļœāļĨāļ›āļĢāļ°āļāļ­āļšāļāļēāļĢāđ€āļœāļĒāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡āļˆāļēāļāļ āļēāļĐāļĩāļ™āļģāđ€āļ‚āđ‰āļē 📉

āļŦāļļāđ‰āļ™āļĒāļļāđ‚āļĢāļ›āļĨāļ”āļĨāļ‡āđ€āļĨāđ‡āļāļ™āđ‰āļ­āļĒāđƒāļ™āļ§āļąāļ™āļĻāļļāļāļĢāđŒ āļ‚āļ“āļ°āļ—āļĩāđˆāļ™āļąāļāļĨāļ‡āļ—āļļāļ™āđ€āļĢāļīāđˆāļĄāļĢāļ°āļ§āļąāļ‡āļ•āļąāļ§āļāđˆāļ­āļ™āļŠāļļāļ”āļŠāļąāļ›āļ”āļēāļŦāđŒāļŠāļļāļ”āļ—āđ‰āļēāļĒāļāđˆāļ­āļ™āļāļēāļĢāđ€āļˆāļĢāļˆāļēāļāļēāļĢāļ„āđ‰āļēāļĢāļ°āļŦāļ§āđˆāļēāļ‡ EU āđāļĨāļ°āļŠāļŦāļĢāļąāļāļŊ āļˆāļ°āļŠāļīāđ‰āļ™āļŠāļļāļ”āļĨāļ‡ āļ”āļąāļŠāļ™āļĩ EU50 āļĨāļ”āļĨāļ‡ 0.2%...

16:56

āļĒāļ­āļ”āļ‚āļēāļĒāļ­āļąāļ‡āļāļĪāļĐāļžāļļāđˆāļ‡ â€“ ECB āđ€āļšāļĢāļāļĨāļ”āļ”āļ­āļāđ€āļšāļĩāđ‰āļĒ

āļ„āļĨāļ·āđˆāļ™āļ„āļ§āļēāļĄāļĢāđ‰āļ­āļ™āļŠāđˆāļ§āļĒāļāļĢāļ°āļ•āļļāđ‰āļ™āļĒāļ­āļ”āļ‚āļēāļĒāļ„āđ‰āļēāļ›āļĨāļĩāļāļ‚āļ­āļ‡āļŠāļŦāļĢāļēāļŠāļ­āļēāļ“āļēāļˆāļąāļāļĢ āļ‚āļ“āļ°āļ—āļĩāđˆāļ„āļ§āļēāļĄāļŦāļ§āļąāļ‡āđƒāļ™āļāļēāļĢāļĨāļ”āļ”āļ­āļāđ€āļšāļĩāđ‰āļĒāļ‚āļ­āļ‡ ECB āđāļ•āļ°āļĢāļ°āļ”āļąāļšāļ•āđˆāļģāļŠāļļāļ” āđāļĄāđ‰āđ€āļĻāļĢāļĐāļāļāļīāļˆāļ‚āļ­āļ‡āļŠāļŦāļĢāļēāļŠāļ­āļēāļ“āļēāļˆāļąāļāļĢāļˆāļ°āļĒāļąāļ‡āđ„āļĄāđˆāļĄāļĩāļŠāļąāļāļāļēāļ“āļŸāļ·āđ‰āļ™āļ•āļąāļ§āđƒāļ™āļŠāđˆāļ§āļ‡āđ„āļĄāđˆāļāļĩāđˆāļŠāļąāļ›āļ”āļēāļŦāđŒāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē...

16:31

āļ•āļĨāļēāļ”āđ€āļ”āđˆāļ™āļ§āļąāļ™āļ™āļĩāđ‰ : GBPUSD

āđ€āļ‡āļīāļ™āļ›āļ­āļ™āļ”āđŒāļ­āļąāļ‡āļāļĪāļĐāđ€āļĢāļīāđˆāļĄāļŠāļđāļāđ€āļŠāļĩāļĒāđāļĢāļ‡āļŠāđˆāļ‡āđƒāļ™āļŠāđˆāļ§āļ‡āļŠāļīāđ‰āļ™āļŠāļąāļ›āļ”āļēāļŦāđŒ āļŦāļĨāļąāļ‡āļ„āļ§āļēāļĄāļ•āļķāļ‡āđ€āļ„āļĢāļĩāļĒāļ”āļĢāļ°āļŦāļ§āđˆāļēāļ‡āđ‚āļ”āļ™āļąāļĨāļ”āđŒ āļ—āļĢāļąāļĄāļ›āđŒāđāļĨāļ°āļ›āļĢāļ°āļ˜āļēāļ™ Fed āđ€āļˆāļ­āđ‚āļĢāļĄ āļžāļēāļ§āđ€āļ§āļĨāļĨāđŒāđ€āļĢāļīāđˆāļĄāļ„āļĨāļĩāđˆāļ„āļĨāļēāļĒ (GBPUSD: -0.25%) āļāļēāļĢāļ›āļĢāļąāļšāļāļēāļ™āļ‚āļ­āļ‡āđ€āļ‡āļīāļ™āļ›āļ­āļ™āļ”āđŒāļĒāļīāđˆāļ‡āļĨāļķāļāļĨāļ‡āđ„āļ›āļ­āļĩāļāļˆāļēāļāļ‚āđ‰āļ­āļĄāļđāļĨāļĒāļ­āļ”āļ„āđ‰āļēāļ›āļĨāļĩāļāļ‚āļ­āļ‡āļŠāļŦāļĢāļēāļŠāļ­āļēāļ“āļēāļˆāļąāļāļĢāļ—āļĩāđˆāļ­āļ­āļāļĄāļēāļ•āđˆāļģāļāļ§āđˆāļēāļ„āļēāļ”...

āđ€āļ‚āđ‰āļēāļŠāļđāđˆāļ•āļĨāļēāļ”āļžāļĢāđ‰āļ­āļĄāļĨāļđāļāļ„āđ‰āļēāļ‚āļ­āļ‡ XTB Group āļāļ§āđˆāļē 1 600 000 āļĢāļēāļĒ

āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ—āļĩāđˆāđ€āļĢāļēāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡ āđ€āļĻāļĐāļŦāļļāđ‰āļ™ (Fractional Shares) āđ€āļ›āđ‡āļ™āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļĩāđˆāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļˆāļēāļ XTB āđāļŠāļ”āļ‡āļ–āļķāļ‡āļāļēāļĢāđ€āļ›āđ‡āļ™āđ€āļˆāđ‰āļēāļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļšāļēāļ‡āļŠāđˆāļ§āļ™āļŦāļĢāļ·āļ­ ETF āđ€āļĻāļĐāļŦāļļāđ‰āļ™āđ„āļĄāđˆāđƒāļŠāđˆāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ­āļīāļŠāļĢāļ° āļŠāļīāļ—āļ˜āļīāļ‚āļ­āļ‡āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ­āļēāļˆāļ–āļđāļāļˆāļģāļāļąāļ”
āļ„āļ§āļēāļĄāļŠāļđāļāđ€āļŠāļĩāļĒāļŠāļēāļĄāļēāļĢāļ–āđ€āļāļīāļ™āļāļ§āđˆāļēāđ€āļ‡āļīāļ™āļ—āļĩāđˆāļāļēāļ